Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: results of the German childhood AML studies BFM-78 and BFM-83

Haematol Blood Transfus. 1990:33:185-92. doi: 10.1007/978-3-642-74643-7_35.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Marrow Transplantation
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Cytarabine / administration & dosage
  • Daunorubicin / administration & dosage
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Germany, West / epidemiology
  • Humans
  • Infant
  • Leukemia, Myeloid, Acute / classification
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / mortality
  • Leukemia, Myeloid, Acute / therapy
  • Life Tables
  • Multicenter Studies as Topic
  • Remission Induction
  • Thioguanine / administration & dosage

Substances

  • Cytarabine
  • Etoposide
  • Doxorubicin
  • Thioguanine
  • Daunorubicin